Salbutamol in cardiogenic shock complicating acute myocardial infarction

J R DAWSON, P A POOLE-WILSON, G C SUTTON

From Hillingdon Hospital, Uxbridge, Middlesex, and Cardiothoracic Institute, 2 Beaumont Street, London

SUMMARY Intravenous salbutamol (13 μg/min) has been given to 31 patients with cardiogenic shock complicating acute myocardial infarction. Haemodynamic measurements were made in nine of these patients. Salbutamol increased cardiac index by 41 per cent from 1.25 ± 0.06 l/min per m² to 1.76 ± 0.19 l/min per m² and decreased systemic vascular resistance by 16 per cent from 26.2 ± 1.9 units to 21.9 ± 2.1 units. Heart rate rose by 13 per cent from 95 ± 4.5 beats/min to 106 ± 6.0 beats/min. Pulmonary artery end-diastolic pressure fell from 20.6 ± 1.7 mmHg to 16.9 ± 1.9 mmHg. Of the 31 patients, eight survived to leave hospital (27%). Five of the survivors had initial low heart rates and in these patients the clinical improvement was probably attributable to the positive chronotropic action of salbutamol. In the remaining three survivors clinical improvement was probably a result of salbutamol mediated afterload reduction. Salbutamol may be useful in the treatment of cardiogenic shock and pump failure complicating acute myocardial infarction.

Vasodilator drugs may improve cardiac performance in heart failure after acute myocardial infarction. Cardiac output is increased by a reduction in systemic vascular resistance (afterload) while myocardial oxygen demand falls as a result of reduced left ventricular wall tension. Salbutamol is a selective beta-2 agonist first introduced for the treatment of bronchial asthma. Animal experiments suggest that its principal cardiovascular effect is a relaxation of vascular smooth muscle producing vasodilation. In man, though the exact mechanism is uncertain, beneficial haemodynamic effects with intravenous salbutamol have been described in patients with mitral valve disease, in low output states after cardiac surgery, and in congestive cardiomyopathy.

Lal et al. treated 12 patients with cardiogenic shock after acute myocardial infarction with intravenous bolus injections of salbutamol (1 to 2 mg). Their report, which does not include haemodynamic data, describes clinical improvement in nine patients, six of whom survived to leave hospital.

We have treated 31 patients with cardiogenic shock after acute myocardial infarction with intravenous salbutamol, and describe the clinical outcome, as well as the haemodynamic responses in nine of them.

Patients

Thirty-one patients with cardiogenic shock complicating acute myocardial infarction comprise the series. Cardiogenic shock was defined as systolic hypotension (< 90 mmHg) associated with oliguria (urine output less than 30 ml/h). All had clinical evidence of low cardiac output (peripheral vasoconstriction and disturbances of consciousness). Twenty-seven patients had radiological evidence of pulmonary oedema. In all patients intravenous frusemide (80 to 500 mg) had been ineffective in promoting a diuresis.

Nineteen patients had anterior and 12 had inferior infarcts; 14 had a previous history of angina or myocardial infarction. Sinus rhythm was present in 24 patients, three were in atrial fibrillation, and four were undergoing temporary pacing for complete heart block complicating the acute infarct.

All patients were given salbutamol by continuous intravenous infusion in a dose of 13 μg/min. Haemodynamic measurements were made at the patient’s bedside in the coronary care unit in nine patients (six men, three women; age range 52 to 68, mean 59) eight of whom were in sinus rhythm, while one was being paced at a fixed ventricular rate of 90 for complete heart block. In the remaining 22 patients (17 men, five women; age range 52 to 72, mean 59) the response to salbutamol was assessed.

Received for publication 23 July 1979
by clinical observation together with measurements of heart rate, blood pressure, and urine output.

**Haemodynamic measurements**

A Swan-Ganz thermodilution catheter (CVI Model No. 600-017) was inserted percutaneously into the right subclavian vein and advanced to the pulmonary artery. Measurements were made of right atrial, right ventricular, pulmonary artery, and wedge pressures. The sternal angle was used as the zero reference point. In all patients pulmonary artery end-diastolic pressure (PAEDP) was found to correlate closely with wedge pressure and in order to avoid frequent catheter manipulations PAEDP was used in most subsequent recordings as an indirect assessment of left ventricular filling pressure. Cardiac output was measured by the thermodilution technique\(^{11}\) using a cardiac output computer (CVI Model No. 600). The injectate was 10 ml normal saline at room temperature. Each value for cardiac output was derived from the average of at least three estimations. Systemic arterial pressure was recorded with an Infrasonde electronic sphygmomanometer (Model No. 3000). Mean arterial pressure was calculated as the diastolic pressure plus a third of the pulse pressure. Heart rate was obtained from an electrocardiogram recorded simultaneously with each measurement of intracardiac pressure and was averaged over 20 beats. Intravenous salbutamol (10 mg in 500 ml, 5% dextrose) was given in a dose of 13 \(\mu\)g/min, the infusion rate being controlled by a Tekmar 51 pump. The intracardiac pressures, cardiac output, heart rate, and arterial pressure were recorded at the beginning and end of a 20-minute control period and then at 10, 20, and 40 minutes after the start of the salbutamol infusion. Cardiac index, stroke index, and systemic vascular resistance

\[
\text{mean arterial pressure} - \text{mean right atrial pressure} = \frac{\text{cardiac output}}{\text{beats/min}}
\]

were calculated. The results recorded are at the end of the control period and at 40 minutes from the start of salbutamol infusion and values are compared using Student's paired t test.

**Results**

In nine patients who had haemodynamic measurements, the changes induced by salbutamol are shown in the Figure. Cardiac index rose in all patients from \(1.25 \pm 0.06 \text{ l/min per m}^2\) to \(1.76 \pm 0.19 \text{ l/min per m}^2\) (41%, \(p < 0.002\)). Stroke index increased by an average of 28 per cent from \(13.2 \pm 0.74 \text{ ml/beats per m}^2\) to \(16.9 \pm 1.4 \text{ ml/beats per m}^2\) (\(p < 0.005\)). Heart rate rose by an average of 13 per cent from \(95 \pm 5 \text{ beats/min}\) to \(107 \pm 6.6 \text{ beats/min}\) (\(p < 0.05\)). Systemic vascular resistance fell from \(26.2 \pm 1.9 \text{ units}\) to \(21.9 \pm 2.1 \text{ units}\) (16%, \(p < 0.02\)).

Pulmonary artery end-diastolic pressure fell from \(20.6 \pm 1.7 \text{ mmHg}\) to \(16.9 \pm 1.9 \text{ mmHg}\) after salbutamol (18%, \(p < 0.05\)). There was a small, though insignificant, increase in mean arterial pressure from \(64.8 \pm 4.1 \text{ mmHg}\) to \(70.3 \pm 4.7 \text{ mmHg}\). After completion of the haemodynamic measurements, all these patients continued treatment with intravenous salbutamol. Two patients (one with an anterior and one with an inferior infarct) survived to leave hospital. In this group there were no appreciable differences in the initial haemodynamic indices between the two survivors and the seven non-survivors. In one patient, a non-survivor, the salbutamol infusion had to be stopped because of the development of supraventricular tachycardia; this was the only complication in the series.

In the 22 patients who did not have haemodynamic measurements there were similar changes in heart rate and mean arterial pressure. Excluding the three patients who were being paced for complete heart block, the heart rate rose from \(88 \pm 5.8 \text{ beats/min}\) to \(101 \pm 4.9 \text{ beats/min}\) (average 15%, \(p < 0.001\)). Mean arterial pressure did not change significantly (mean \(71 \pm 3 \text{ mmHg}\) before, and mean \(74 \pm 3 \text{ mmHg}\) (average 4%). Six patients from this group (four with inferior and two with anterior infarcts) survived to leave hospital. Initial heart rate (\(63 \pm 2.5 \text{ beats/min}\)) was significantly lower in the survivors than in the non-survivors (\(99 \pm 9.1 \text{ beats/min}\)) (\(p < 0.005\)).

Urine output was measured in all patients and increased from a mean of \(9 \pm 1.7 \text{ ml/h}\) to a mean of \(72 \pm 22.6 \text{ ml/h}\) after salbutamol (\(p < 0.01\)).

**Discussion**

Clinical evidence of cardiogenic shock with pump failure was present in all patients with systemic hypotension, peripheral vasoconstriction, oliguria, and in most cases pulmonary oedema. In nine patients in whom haemodynamic measurements were made, the extremely low initial cardiac outputs further emphasise the severity of pump failure present in these patients. Salbutamol significantly increased cardiac index, stroke index, and heart rate while reducing systemic vascular resistance and left ventricular filling pressure. The percentage rises in cardiac index (41%) and fall in systemic
vascular resistance (16%) are similar to those changes noted by ourselves,12 and by Sharma and Goodwin9 in patients with chronic heart failure treated with intravenous salbutamol. The increase in heart rate (13%) is similar to that found by Gibson and Coltart6 in patients with mitral valve disease and by Poole-Wilson et al.4 in patients after open heart surgery but was a less striking feature of our patients with chronic heart failure.

The exact mode of action of salbutamol on the human cardiovascular system is not clearly established. Cullum et al.2 working with animals, showed that salbutamol has 1/10 the activity of isoprenaline on vascular smooth muscle but only 1/2000 its activity in increasing heart muscle tension. This implies that the increased cardiac output noted with salbutamol is principally a result of vasodilatation secondary to beta-adrenergic stimulation of vascular smooth muscle rather than a direct cardiac effect. This finding, that salbutamol has a negligible effect on heart muscle beta-adrenergic receptors, was confirmed by Nayler4 working with isolated human heart muscle preparations. In addition, Nayler showed that in dog preparations there was evidence of salbutamol mediated direct coronary artery dilatation which is not dependent upon an increase in myocardial oxygen demand. The results of these in vitro experiments tend to conform with the findings in the majority of reports on patients with heart disease,6 7 8 12 though Sharma and Goodwin,9 whose patients had congestive cardiomyopathy, concluded that salbutamol induced increases in cardiac output are a result of positive inotropic stimulation.

We believe that the increased cardiac output observed in our patients was probably a result of vasodilatation rather than a positive inotropic effect. In preparations of isolated rabbit papillary muscle the minimum concentration of salbutamol required to produce a positive inotropic effect is 0.09 mg/l,12 10 times the estimated serum concentration of salbutamol in man that would be achieved by an infusion rate of 13 µg/min.

An increase in heart rate was observed in the majority of our patients and appears to have been beneficial in some, though excessive increases in

![Graph showing changes in cardiac index, heart rate, pulmonary artery end-diastolic pressure (PAEDP), mean blood pressure (BP), systemic vascular resistance (SVR), and stroke index with salbutamol.](http://heart.bmj.com/)

**Fig.** The changes in cardiac index, heart rate, pulmonary artery end-diastolic pressure (PAEDP), mean blood pressure (BP), systemic vascular resistance (SVR), and stroke index with salbutamol.
heart rate may be detrimental to an already ischaemic myocardium by increasing myocardial oxygen consumption. The mechanism of the increase in heart rate was not determined.

In this study, eight patients (27%) survived to leave hospital. This survival rate is similar to previously reported rates in patients with cardiogenic shock complicating myocardial infarction. In five of the survivors (four inferior and one anterior infarct) initial heart rate was inappropriately low. The chronotropic action of salbutamol may have been responsible for the clinical improvement observed in these patients. In the remaining three survivors (two anterior and one inferior infarct) initial heart rate was high (mean 92 beats/min), and in the two patients for whom haemodynamic data are available the initial haemodynamic indices in survivors were the same as in non-survivors. In these patients improved cardiac performance was probably mediated by salbutamol induced afterload reduction. Though a non-survivor, one patient who had measured haemodynamic responses was being paced for complete heart block. This patient had similar increases in cardiac output and stroke index, and similar falls in systemic vascular resistance and left ventricular filling pressure as the remaining eight patients, though heart rate of course remained constant.

Vasodilators are now widely advocated in the treatment of pump failure after acute myocardial infarction though survival rates are low. Sodium nitroprusside, phentolamine, glyceryl trinitrate, and isosorbide dinitrate have all been shown to have beneficial haemodynamic effects. Our findings suggest that, though survival was disappointingly low in spite of treatment, salbutamol is a valid alternative drug in the management of pump failure and cardiogenic shock complicating acute myocardial infarction.

We thank Allen & Hanbury Ltd for supplying the intravenous salbutamol.

References


Requests for reprints to Dr G C Sutton, Hillingdon Hospital, Uxbridge, Middlesex UB8 3NN.
Salbutamol in cardiogenic shock complicating acute myocardial infarction.

J R Dawson, P A Poole-Wilson and G C Sutton

*Br Heart J* 1980 43: 523-526
doi: 10.1136/hrt.43.5.523

Updated information and services can be found at:
http://heart.bmj.com/content/43/5/523

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/